Nutraceutical or food: decide the lane first
In India the same capsule can be an ordinary food, a health supplement, a nutraceutical or a drug. The lane decides your licence, your pack and your claims. Most brands lock the formula first and discover the lane afterwards, which is the expensive order.
- The food to supplement line turns on composition, form and concentration. The supplement to drug line turns on intended use. They are different tests and brands usually learn only one.
- Dosage form does not by itself make a product a drug in India, but form and dose interact. A 2021 amendment caps nutrients at one RDA and allows the higher route only in food format, not tablet, capsule or syrup.
- Purified single chemical entities and novel foods need prior approval from the Food Authority before commercial manufacture or sale, which is not a month-nine discovery.
- Settle the category on the spec sheet. Licence class, mandatory pack declarations and permitted claims all inherit it, and changing it later usually means changing the product.
Most supplement brands in India settle the formula first. The regulatory category gets decided later, often by whoever fills in the licence application. That is the wrong order, and it is expensive. The category sets what the pack must say, what an advertisement may claim, which regulator can act, which licence class you need and whether a platform will switch the listing live at all. Reversing it afterwards means reversing the product.
This is operational guidance and not legal or regulatory advice. The notified text and your own licence class govern.
Three lanes, two different tests
Section 3(1)(j) of the Food Safety and Standards Act, 2006 defines food as any substance intended for human consumption, then excludes a short list from it: animal feed, live animals, plants before harvest, drugs and medicinal products, cosmetics, narcotic or psychotropic substances. So the outer boundary is definitional. If the product is a drug, it is not food, and the food regulator is not your regulator.
Inside food, a second boundary separates ordinary food from the specialised categories. Those sit in the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, which cover health supplements, nutraceuticals, food for special dietary use, food for special medical purpose, foods with added probiotic or prebiotic ingredients, specialty food containing plant or botanical ingredients, and novel food.
The part worth internalising is that the two boundaries are drawn by different tests. The food to supplement line turns on composition, form and concentration. The supplement to drug line turns on intended use. Brands that learn one test get caught by the other.
What pushes a product out of ordinary food
Under the 2016 regulations a health supplement is a concentrated source of one or more nutrients or other substances with a known nutritional or physiological effect, offered alone or in combination. Two constraints follow that founders rarely read.
First, a health supplement cannot be a product for which a specific standard has already been laid down elsewhere in the regulations. If a standard exists for the thing you are making, you are making that thing, not a supplement version of it. Second, the ingredients have to come from the schedules annexed to the regulation and the additives from the additive schedules. FSSAI runs a Food Product Identity Verification System, at fssai.gov.in/fpivs, to check ingredients against those schedules.
There is a further gate that catches purified actives. The regulations state that any single purified chemical entity listed in them, other than botanical extracts, intended for sale as a health supplement, nutraceutical, food for special dietary use or food for special medical purpose, is not permitted without prior approval of the Food Authority. Novel food carries its own requirement of prior approval before commercial manufacture or import.
What pulls it towards a drug
Section 3(b) of the Drugs and Cosmetics Act, 1940 defines a drug to include all medicines for internal or external use and all substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder. The operative word is intended, and intention is read from how the product is presented. That is why the same capsule can sit in two different lanes depending on the words printed around it.
A second limb covers substances, other than food, intended to affect the structure or any function of the human body, but only as specified by the Central Government by notification. The 2016 regulations close the loop from the other side by requiring that the substances in a health supplement are not drugs as defined in that clause. The same Act also runs a separate stream for Ayurvedic, Siddha and Unani drugs, with its own analysts and inspectors appointed under separate sections, so a botanical formulation has more than two possible homes.
The practical read is uncomfortable: you do not enter the drug lane by applying for it, you get placed in it by what the product is and how you present it.
Form and concentration decide more than intent
A widespread assumption is that a tablet or capsule makes a product a drug. In India that is not the test. The 2016 regulations expressly allow health supplements in dosage forms including capsules, tablets, pills, sachets, gels, semi-solids, and liquids and powders designed to be taken in measured unit quantities.
Where form does bite is in combination with concentration. An amendment to the regulations in force from 6 September 2021, with compliance required by 1 April 2022, requires nutrients to be added at levels equal to a maximum of one Recommended Dietary Allowance or below, and permits a higher-RDA product only in food format, expressly excluding tablet, capsule and syrup, and only with prior approval of the Food Authority based on adequate scientific evidence. So dose and format are not independent decisions. Choose a high-dose capsule and you have closed the only route that would have taken you above one RDA.
Purity follows the same pattern. Where FSSAI has not notified a criterion, the regulations point to named pharmacopoeias and standards. That is a sourcing constraint on your supplier, not a filing detail.
Run the lane check while the formula is still soft
The category is not invisible once you ship. The regulations require a health supplement pack to carry the words HEALTH SUPPLEMENT and a nutraceutical pack the word NUTRACEUTICAL, each with a prominent NOT FOR MEDICINAL USE advisory and the nutrient quantity expressed against the relevant recommended daily allowance. Your lane is printed on the front of the product.
So work it in this order. Write the intended effect in one sentence, in the words you plan to use in market, and test it against the drug definition rather than your own comfort. List every ingredient with its concentration and check each against the schedules. Choose the format knowing the concentration ceiling attached to it. Only then cost the formula.
Everything downstream inherits the choice. The licence class follows the category, covered in FSSAI licence basics for food sellers. The panel on the pack is a separate discipline, covered in nutrition labelling and allergen rules for D2C. The evidence behind anything you say is covered in holding a claim substantiation file. And if you change the formula later, the ripple runs wider than the recipe, as set out in the downstream consequences of reformulation.
Brands that get this right treat classification as a product decision with a regulator attached. Brands that get it wrong find out when a batch is already made.